Lyell Immunopharma, Inc.·4

Feb 28, 6:15 PM ET

Thompson Rahsaan 4

4 · Lyell Immunopharma, Inc. · Filed Feb 28, 2023

Insider Transaction Report

Form 4
Period: 2023-02-24
Thompson Rahsaan
Chief Legal Officer
Transactions
  • Award

    Option (right to buy)

    2023-02-24+245,000245,000 total
    Exercise: $2.13Exp: 2033-02-23Common Stock (245,000 underlying)
Footnotes (1)
  • [F1]12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION